These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2813178)

  • 1. [Antiestrogens in the treatment of advanced breast cancer].
    Płuzańska A; Smiałowska A; Stempczyńska J; Wator A
    Pol Tyg Lek; 1989 Feb 13-20; 44(7-8):191-4. PubMed ID: 2813178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
    Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer].
    Hisamatsu K; Nomura Y; Tashiro H
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2017-23. PubMed ID: 1417009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response to rechallenged tamoxifen of metastatic breast cancer relapsed after surgical adjuvant tamoxifen treatment].
    Abe O; Nomura Y; Izuo M; Tominaga T; Koyama H; Tashiro H
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1333-6. PubMed ID: 2069403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.
    Ahn PH; Vu HT; Lannin D; Obedian E; DiGiovanna MP; Burtness B; Haffty BG
    J Clin Oncol; 2005 Jan; 23(1):17-23. PubMed ID: 15545666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study.
    Hoogstraten B; Fletcher WS; Gad-el-Mawla N; Maloney T; Altman SJ; Vaughn CB; Foulkes MA
    Cancer Res; 1982 Nov; 42(11):4788-91. PubMed ID: 7127314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial].
    Jouve M; Palangie T; Dorval T; Garcia-Giralt E; Asselain B; Coutant M; Magdelenat H; Pouillart P
    Bull Cancer; 1987; 74(3):249-60. PubMed ID: 3304479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day].
    Takatsuka Y; Yayoi E; Inaji H; Aikawa T
    Gan To Kagaku Ryoho; 1989 May; 16(5):2093-7. PubMed ID: 2658841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [UFT-MT therapy in advanced or recurrent breast cancer].
    Yamaguchi S; Komoriyama H; Tsukikawa S; Imaki S; Morikubo M; Asakura T; Okamura R; Fukuda M; Kanasugi K; Watanabe H
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2437-41. PubMed ID: 2124435
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
    Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
    Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
    Nomura Y; Nakajima M; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].
    Nomura Y; Abe O; Izuo M; Inoue K; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1863-71. PubMed ID: 3382238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?
    Bhatavdekar JM; Patel DD; Karelia NH; Shah NG; Ghosh N; Vora HH; Suthar TP; Balar DB; Doctor SS
    Eur J Surg Oncol; 1994 Apr; 20(2):118-21. PubMed ID: 8181575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
    Skowronek J; Piotrowski T
    Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.